AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Suppressive TX cuts transmission of genital herpes: susceptible partners in the valacyclovir group got 50% fewer HSV-2 infections. (Randomized, Controlled Trial).
SAN DIEGO -- Once-daily valacyclovir halved transmission rates of herpes simplex virus 2 in the first randomized, controlled trial to show that an antiviral medication can reduce the spread of a sexually transmitted disease.
The results address the "biggest fear" of couples in which one partner has genital herpes and the other doesn't--that they will give herpes or get it from their partner, Dr. Lawrence Corey said at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
The multicenter, 8-month study included 1,484 heterosexual, monogamous couples in which one partner had genital herpes simplex virus 2 (HSV-2) and the other partner was uninfected. Infected partners were randomized to once-daily treatment with 500-mg valacyclovir or placebo. GlaxoSmithKline, which makes valacydovir, funded the study.
At monthly visits, investigators drew blood from the uninfected "susceptible" partners to test for HSV-2 antibodies; checked the infected "source" partners' adherence to therapy; collected sexual history diaries from all participants; and provided counseling advocating the use of condoms during sex.
Overall, 14(2%) of 743 susceptible partners in the valacyclovir group acquired symptomatic or asymptomatic HSV-2 infection, compared with 28(4%) of 741 susceptible partners in the placebo group--a 50% reduction in the rate of transmission, said Dr. Corey, professor of medicine and laboratory medicine and head of the virology division at the University of Washington, Seattle.
Suppressive therapy appeared to be even more effective in reducing the risk of symptomatic HSV-2 infection. Four (0.5%) susceptible partners in the valacyclovir group developed a first episode of anogenital herpes, compared with 17 (2.3%) susceptible partners in the placebo group--a 77% reduction in the risk for clinical HSV-2.
Suppressive therapy also reduced symptoms in the source partners: Only 40% of ...
- Corey, L., Wald, A., Patel, R., et al. (2004). Once-daily valacyclovir to...
- Magazine article from: The Canadian Journal of Human Sexuality McKay, Alexander June 22, 2003 700+ words
...4 of the 743 susceptible partners of source partners...assigned to the valacyclovir group as compared to 16 of the 741 susceptible partners of source partners...in 14 of the susceptible partners in the valacyclovir group (1.9...
- Drug approved for lowering herpes transmission risk: for use in heterosexuals:...
- Magazine article from: OB GYN News Mechcatie, Elizabeth October 1, 2003 700+ words
...transmission of genital herpes to susceptible partners. The approval is limited to otherwise...were randomized to placebo. Their susceptible partners had no history of genital herpes...the study, significantly fewer susceptible partners had become infected in the treatment...
- Valacyclovir in pregnancy limits herpes recurrence.(News)
- Magazine article from: OB GYN News Johnson, Kate June 1, 2005 700+ words
...presence of HSV (4% in the valacyclovir group versus 12.5% in the placebo group). The valacyclovir group also had a lower percentage of...who participated, 2% in the valacyclovir group and 9% in the placebo group...
- Valacyclovir as good as Acyclovir for prevention of ocular herpes.(Infectious...
- Magazine article from: Skin & Allergy News Finn, Robert October 1, 2007 700+ words
...therapy, six of the patients in the valacyclovir group and six of the patients in the acyclovir...side effects. Three patients in the valacyclovir group and four patients in the acyclovir...vomiting, and five patients in the valacyclovir group and three patients in the acyclovir...
- A New Treatment for Vestibular Neuritis.
- Newspaper article from: Neurology Alert September 1, 2004 700+ words
...methylprednisolone group, 36.0 [+ or -] 26.7 percentage points in the valacyclovir group, and 59.2 [+ or -] 24.1 percentage points in the methylprednisolone plus valacyclovir group. Analysis of variance showed that methylprednisolone, but...
- Valacyclovir clears EBV in mono, may also restrict spread.(News)(epstein-barr...
- Magazine article from: Pediatric News Tucker, Miriam E. February 1, 2006 700+ words
...those treated with valacylovir versus 1 of 10 control subjects. The oral viral load decreased more rapidly in the valacyclovir group, becoming undetectable in most of the treated subjects, Dr. Balfour said. Reductions in whole blood viral...
- Valacyclovir clears EBV in mono, may help prevent spread.(News)(Epstein-Barr...
- Magazine article from: Family Practice News Tucker, Miriam E. January 15, 2006 700+ words
...those treated with valacylovir versus 1 of 10 control subjects. The oral viral load decreased more rapidly in the valacyclovir group, becoming undetectable in most of the treated subjects, Dr. Balfour said. Reductions in whole blood viral...
- New genital herpesvirus study findings have been published by M. Abudalu and...
- Newspaper article from: Virus Weekly September 16, 2008 700+ words
...The overall incidence of adverse events was similar (23.2% for the famciclovir group vs. 22.3% for the valacyclovir group), with headache, nausea, diarrhea, vomiting, and abdominal pain reported most often," wrote M. Abudalu...
Source: HighBeam Research, Suppressive TX cuts transmission of genital herpes: susceptible...